

	<p>Neill Liptrott, Ph.D.</p>		
<p>Organisation</p>	<p>University of Liverpool</p>		
	<p>Dr Liptrott has a background in pharmacology, immunology and cell biology. His research is specifically focused on investigating the interactions between nanoparticles and biological systems, with a focus on immunological interactions. Using standardised analysis and screening techniques Dr Liptrott is building structure-activity relationships between nanomaterial characteristics and their impact on biological systems. This extends to the determination of immunological safety of conventional and nanotechnology-enabled medicines. An understanding of the interaction of nanomaterial with immunological and haematological systems is vital to preclinical evaluation as well as enabling future rational design of nanomaterials. Dr Liptrott’s research to date has helped underpin the successful translation of solid drug nanoparticle formulations through GMP manufacture towards a healthy volunteer bioequivalence study planned for Q4 2015. Dr Liptrott also worked as a guest researcher at the National Cancer Institute’s (NCI) Nanotechnology Characterisation Laboratory (NCL) based in Frederick, Maryland, USA. During his sabbatical at US-NCL Dr Liptrott strengthened the ongoing collaboration ULP have with NCI-NCL via Dr Marina Dobrovolskaia and further refined the experimental cascade used at ULP. Dr Liptrott will join the core expert team (CET) and will deliver all aspects of the Liverpool experimental contribution to activities.</p>		
<p>Role in the EU-NCL</p>	<p>Neill is Member of the Executive Board (ExBo), Core Expert Team (CET) and leads the immunology/haematology work package for ULP. Additionally Neill is co-leader of the trend analysis work package.</p>		